SCHEMBL304704

SCHEMBL304704

CN(CC#N)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
GRM5 P41594 1/20 0.45
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TAAR1 Q96RJ0 2/20 0.38
CRHBP P24387 2/20 0.37
CRHR2 Q13324 2/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
AOC3 Q16853 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP2D6 P10635 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28482465 0.83 TDP1 (0.56) MAOBGRM5CA12CA2CA9
SCHEMBL6553719 0.80 MAOB (0.34) MAOBGRM5
SCHEMBL6675221 0.80 GLA (0.47) MAOBGRM5MEN1KMT2AMAPT
SCHEMBL9174261 0.78 CYP2A6 (0.43) CA12CA2CA9KMT2AALDH1A1
SCHEMBL149631 0.78 ALDH1A1 (0.49) CA12CA2CA9MEN1KMT2A
SCHEMBL5148459 0.78 APP (0.39) MAOBHTTTAAR1MAPTAOC3
SCHEMBL6671505 0.78 PYCR1 (0.39) MAOBMEN1KMT2ATAAR1MAPT
SCHEMBL6929485 0.77 CA12 (0.47) MAOBGRM5CA12CA2CA9
SCHEMBL5982497 0.77 MAOB (0.53) MAOBGRM5CA12CA2CA9
SCHEMBL8331122 0.77 GRM5 (0.53) MAOBGRM5CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114195640-B Synthesis process of hydroxytyrosol and intermediate thereof 攀枝花学院 2024-03-12 CN disclosed
US-20230303568-A1 INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME MEDPACTO INC. (KR) 2023-09-28 US disclosed
CN-113264881-B Synthetic method of alpha-cyanide 南昌大学 2022-12-02 CN disclosed
CN-113264881-A Synthetic method of alpha-cyanide 南昌大学 2021-08-17 CN disclosed
US-10689504-B2 Two part curable composition Henkel IP & Holding GmbH (DE) 2020-06-23 US disclosed
US-20190023872-A1 TWO PART CURABLE COMPOSITION HENKEL AG & CO. KGAA (DE) 2019-01-24 US disclosed
US-9969690-B2 Cure accelerators for anaerobic curable compositions Henkel IP & Holding GmbH (DE) 2018-05-15 US disclosed
US-9969690-B2 Cure accelerators for anaerobic curable compositions Henkel IP & Holding GmbH (DE) 2018-05-15 US disclosed
WO-2017172270-A1 TWO PART CURABLE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2017-10-05 WO disclosed
US-20170174630-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2017-06-22 US disclosed
EP-1174419-A1 A method for producing an alpha-aminonitrile from a tertiary amine and a cyanide through oxidation with oxygen by using a transition metal catalyst OSAKA UNIVERSITY (JP) 2002-01-23 EP disclosed
EP-0803083-B1 IMAGE-RECORDING MATERIALS POLAROID CORP (US) 1999-04-21 EP disclosed
EP-0664999-B1 Use of heat curable compositions as dental material IVOCLAR AG (LI) 1999-03-24 EP disclosed
EP-0803083-A1 IMAGE-RECORDING MATERIALS POLAROID CORPORATION (US) 1997-10-29 EP disclosed
US-5674986-A FOR HEAT-DEVELOPABLE PHOTOSENSITIVE IMAGE-RECORDING MATERIALS POLAROID CORPORATION (US) 1997-10-07 US disclosed
WO-1997018497-A1 IMAGE-RECORDING MATERIALS POLAROID CORPORATION (US) 1997-05-22 WO disclosed
US-5569574-A CONTAINING CYCLIC 1,3-SULFUR-OXYGEN MOIETY; DIFFUSION TRANSFER PROCESSES POLAROID CORPORATION (US) 1996-10-29 US disclosed
US-5539017-A BETA-DICARBONYL COMPOUNDS AND ALPHA,BETA-UNSATURATED ESTERS OF CARBOXYLIC ACIDS IVOCLAR AG (LI) 1996-07-23 US disclosed
EP-0664999-A1 Use of heat curable compositions as dental material IVOCLAR AG (LI) 1995-08-02 EP disclosed
US-4159192-A CYANO-METHINE DYES CIBA-GEIGY AG (CH) 1979-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174630-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS AHCY, AHCYL1, CAPG MAOB 3041/4885GRM5 1368/4885CA12 1642/4885
US-20230303568-A1 INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME TGFB1, TGFBR1, TGFB2 MAOB 1076/4885GRM5 4288/4885CA12 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.